Andy Studna, Senior Editor

In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.

Combination demonstrated a favorable trend toward overall survival in non-small cell lung cancer patients.

Systematic review of 127 recent platform trials showed insufficient reporting of important trial information.

Despite improvements, results from the study of SLS-005 (IV trehalose), a low molecular weight disaccharide, did not meet statistical significance.

Results of cross-sectional study of 50 discharge summaries suggest a large language model can be used to increase their understandability.

Analysis of trial results show Imfinzi and Lynparza displayed a strong clinical benefit and more than doubled median duration of response vs. chemotherapy.

Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients based on results from the pivotal Phase III KarMMa-3 study.

Cross-sectional study of recent FDA drug approvals evaluated how closely they were aligned with US and global burden of disease.

Collaboration brings Flatiron’s oncology-specific decision support platform to oncology care clinicians at MUSC Hollings Cancer Center.

Effective immediately, the acquisition strengthens both organizations’ abilities to recruit and retain diverse populations for clinical trials.

Tola Olorunnisola, senior vice president – general manager, clinical services and strategy, at Avantor, discusses the progress and challenges in incorporating more diversity-driven measures in drug development.

Investigational, once-weekly combination shows promise as long-acting oral treatment option for those virologically suppressed with HIV.

Gilead’s Veklury (remdesivir), a nucleotide analog prodrug, was associated with lower risk of developing long-COVID.

Gadi Saarony, CEO of Advarra discusses the current state of diversity in clinical trials and how industry needs to be more proactive in addressing it.

Elysium Therapeutics’ proprietary O2P is a hydrocodone prodrug for the treatment of moderate-to-severe acute pain.

While little research on open-cohort designs currently exists, could this design be a solution to challenges currently seen in closed-cohort designs?

DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR).

With inequalities in palliative care provisions, recent study seeks to create a more equitable, diverse, and inclusive framework based on Patient and Public Involvement.

With significant race and sex disparities in the area of peripheral artery disease, a study shows that clinical trials often lack representative patient populations.

VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Gilead’s Biktarvy is now the first and only INSTI-based single-tablet regimen that is FDA approved and DHHS guideline recommended for people who are virologically suppressed with M184V/I resistance.

Biopharma company XYRA and FDA have concluded a series of Phase II meetings on managing key studies for potential atrial fibrillation therapy, budiodarone.

In an interview with ACT Editor Andy Studna, Gadi Saarony, CEO of Advarra talks about using technology to better diversify clinical trials and what to expect in the new year.

Phase Ia, open-label, escalating dose study to evaluate the safety and immunogenicity of therapeutic vaccine, TherVacB.

In an interview with ACT Editor Andy Studna, Gadi Saarony, CEO, Advarra, offers his thoughts on the status of the pharmaceutical industry improving diversity in clinical trials.

Enrollment and initial follow up has been completed for study set to test efficacy of cancer vaccine in individuals with Lynch syndrome.

Clinical-stage biotech’s lead drug candidate, PrimeC for the treatment of ALS demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients.

ARV-102 is a novel oral PROTAC protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2.

Upgrades include end-of-life equipment replacements and relocation.

Phase II GenePHIT trial is evaluating the safety and efficacy of a single intracoronary infusion of AB-1002.